Category Archives: Cancer and neoplasms

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Abstract Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult […]

Texture and color enhancement imaging improves the visibility of gastric neoplasms: clinical trial with image catalogue assessment using conventional and newly developed endoscopes

Patients and study design This was a single-center, prospective trial. We prospectively enrolled patients who were diagnosed with gastric neoplasms (including adenoma and adenocarcinoma) through endoscopic and histological diagnosis, and who were referred to our hospital for treatment. Patients were enrolled as consecutive cases in this study to eliminate selection bias. Written informed consent was […]

Decoding γδ T cell anticancer therapies: integrating CRISPR screens with tumor organoids

In a recent publication in Nature,1 Mamedov and colleagues identified pathways that modulate γδ T cell killing and BTN3A cellular expression through integrating genome-wide CRISPR screens and tumor organoid culture, deepening our comprehension of γδ T cell stress surveillance and proposing novel pathways to boost γδ T cell’s anticancer functions (Fig. 1). Fig. 1 Vγ9Vδ2 […]

Case series of ovarian neuroendocrine carcinoma: overview of clinicopathological features

The pathogenesis of primary O-NECs is not well understood. These tumors are primarily classified into three histological types: SCCs (hypercalcemic, pulmonary types), carcinoid (insular, trabecular, goiter, mucinous carcinoid, mixed types), and large cell NEC [1]. At present, there is limited clinical understanding regarding the incidence, histogenesis, treatment, and prognosis of this disease. In this report, […]

New cancer plans focus on Aboriginal health and priority populations  

Although cancer care has improved dramatically in Australia over the past few decades, two new cancer plans have been unveiled focusing on improving outcomes for priority population groups and Aboriginal and Torres Strait Islander peoples. Two new cancer plans, one launched by the Australian Government and the other developed by the peak body for Aboriginal […]

Mohammed Dabbour, cancer pathologist, killed in Gaza

Skip to navigation Skip to content Scroll to top Subscription Change This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level. OK Cancel Request Cancellation Renew today! Your subscription has lapsed. Subscribe today to access this content. Subscriber content Log in or subscribe to […]

Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene

Introduction The ETV6::PDGFRB fusion gene is commonly associated with myeloid neoplasms with monocytosis (such as CMML), and with eosinophilia.1 The PDGFRB gene, located on 5q33, encodes PDGFRβ, a type III tyrosine kinase comprising an extracellular domain consisting of five immunoglobulin (Ig)-like domains, a single-transmembrane helix domain, a juxtamembrance domain, and an intracellular tyrosine kinase domain.2 […]

Anticancer drugs vs no anticancer drugs for advanced HBCs

Introduction Hepatobiliary cancers (HBCs) —including hepatocellular carcinoma, intra- and extra-hepatic cholangiocarcinoma, and gallbladder cancer— represent more than 5% of all new cancers worldwide, constituting the third cause of death.1,2 A considerable proportion of patients are diagnosed in advanced stages (17.9% for liver and intrahepatic bile duct cancer and 44.3% for gallbladder cancer) with a lack […]